Evotec SE stock (DE0005664809): Q1 update keeps focus on biotech pipeline after Nasdaq delisting

Evotec SE has reported first-quarter 2025 results and finalized its voluntary Nasdaq delisting, keeping attention on the German biotech group’s discovery and development platforms and partnerships with large pharma companies.

Evotec SE has remained in focus with the publication of its first-quarter 2025 results and the recently completed voluntary delisting of its American Depositary Shares from Nasdaq, while the primary listing continues in Frankfurt. The Hamburg-based biotech reported continued investment in its global research platforms and reiterated its focus on partnering with major pharmaceutical and biotech companies, according to a quarterly update released on May 14, 2025, and subsequent disclosures on its website, as reported by the company and European exchange filings in mid-May 2025.

In the Q1 2025 update, Evotec highlighted the performance of its discovery and development segments and emphasized cost discipline after a period of elevated investment in capacity and technology. The company, which works with partners across therapy areas such as neurology, metabolic diseases, oncology, and infectious diseases, also addressed the implications of its completed Nasdaq delisting, first announced in early 2025 and carried out later that year, according to company communications and German regulatory filings as of May 2025. For US investors, the main access route to Evotec equity is now via its German listing or over-the-counter trading, while the underlying business model and partnerships remain global in scope.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Biotechnology / drug discovery and development services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Partnered discovery alliances, development milestones, research services, and potential royalty streams
• Home exchange/listing venue: Frankfurt Stock Exchange (Prime Standard; ticker typically EVT)
• Trading currency: Euro (EUR)

Evotec SE: core business model

Evotec SE operates as a biotechnology and drug discovery company that focuses on providing integrated research and development solutions to pharmaceutical and biotech partners worldwide. Instead of concentrating on a single in-house drug portfolio, Evotec has built a platform-based business model, combining proprietary technologies, scientific expertise, and global infrastructure to support partners from early target identification through to clinical development. The company aims to participate in the value created by partnered projects through a mix of service revenues, milestone payments, and, in some cases, potential future royalties on commercialized drugs.

The core of Evotec’s business lies in early-stage discovery, where it offers target discovery, high-throughput screening, hit-to-lead, and lead optimization services. These activities are underpinned by advanced screening technologies, compound libraries, and data-driven approaches that allow partners to test large numbers of chemical entities against biological targets. The company also maintains specialized platforms for biologics, cell therapies, and induced pluripotent stem cell (iPSC) technologies, helping address complex diseases such as neurodegenerative and metabolic disorders. This platform orientation enables Evotec to work on numerous programs in parallel, diversifying its exposure across therapeutic areas and partners.

In addition to discovery services, Evotec is active in preclinical development and selected clinical stages, where it can provide safety assessment, pharmacology, and translational research capabilities. The company often structures collaborations so that it receives an upfront service component, followed by potential success-based payments as research milestones are achieved. This approach can align incentives with partners and create long-term value if partnered assets advance successfully through the pipeline. However, it also exposes Evotec to the typical uncertainties of drug development, as progression through each stage depends on scientific and regulatory outcomes that may be difficult to predict.

Evotec has steadily expanded its network of collaborations with large pharmaceutical companies, mid-size biotechs, and academic institutions. Over the past several years, it has pursued a strategy of building thematic platforms around specific disease areas, such as metabolic diseases or precision medicine in oncology, and then partnering these platforms with multiple stakeholders. By doing so, Evotec aims to leverage its internal capabilities across a broader set of programs, while partners contribute disease-specific expertise, clinical development resources, and commercial infrastructure. The scaling of this model depends on Evotec’s ability to maintain high scientific quality, retain key talent, and keep its infrastructure and technologies competitive.

Main revenue and product drivers for Evotec SE

Evotec’s revenue base is primarily generated from discovery and development services provided to its partners, as well as from milestones tied to the advancement of specific programs. In its financial communications for full-year 2024, the company described a revenue mix consisting of base service revenues from research collaborations, as well as variable components related to project success, according to its annual results presentation released in March 2025, as documented in company reports and German regulatory disclosures as of March 2025. Service revenues tend to be relatively predictable over the short term as they are linked to ongoing contracts, while milestones and potential royalties introduce more variability and longer-term upside.

Another important revenue driver for Evotec is its portfolio of co-owned or partnered pipeline assets, where the company may hold rights to receive milestones and royalties if products reach commercialization. This portfolio spans a range of therapeutic areas, including central nervous system diseases, diabetes, kidney disease, oncology, and infectious diseases. In its annual communications, Evotec has highlighted several partnered programs that have advanced into clinical stages, including candidates in metabolic and kidney diseases developed in collaboration with large pharmaceutical partners, according to company reporting in 2024 and early 2025. The potential future royalties from such programs are difficult to forecast but could contribute meaningfully to revenues if the drugs are approved and achieve significant sales.

Evotec’s investments in proprietary platforms such as iPSC-based disease modeling and precision medicine also play a role in future revenue potential. By creating differentiated capabilities around patient-derived cell models and complex biology systems, the company seeks to offer partners more predictive research tools that can potentially reduce attrition rates in clinical development. These platforms may justify premium pricing for certain services and could also underpin new co-owned programs with improved probabilities of success. The balance between investing in these capabilities and maintaining profitability has been a recurring theme in the company’s financial updates, with management pointing to the need to prioritize programs and optimize resource allocation, according to its strategy commentary in 2024 and 2025 company presentations.

For many US investors, Evotec’s role as an external research partner to large pharmaceutical firms is a key point of interest. Major drug makers increasingly outsource parts of their discovery pipelines to specialized companies, and Evotec positions itself as a preferred partner for segments of this work. The company’s ability to win and retain large, multi-year contracts with global pharma is therefore a significant driver of medium-term revenue visibility. Contract announcements, expansions of existing alliances, and the progression of partnered programs into later development stages are all events that can influence expectations around Evotec’s revenue trajectory and profitability over time.

Why Evotec SE matters for US investors

Even after the company’s voluntary delisting of its American Depositary Shares from Nasdaq, Evotec SE remains relevant for US investors due to its global partner base and exposure to innovation in drug discovery. Large US pharmaceutical and biotech companies continue to be key partners for Evotec, and the outcomes of these collaborations can influence the broader healthcare investment landscape. The company’s activities help feed the early-stage pipelines of numerous US-listed pharma players, meaning that progress at Evotec can indirectly affect drug candidates that might later appear in the portfolios of US large caps.

From an access standpoint, Evotec’s primary listing on the Frankfurt Stock Exchange and trading in euros introduce additional considerations for US investors. Currency movements between the euro and the US dollar can affect the translated value of any holdings, and trading hours differ from US markets. Some US investors may gain exposure via international brokerage platforms that support direct trading on European exchanges or through over-the-counter instruments. In all cases, investors generally need to pay attention to liquidity, spreads, and any additional fees associated with foreign trading.

Another factor for US market participants is the company’s focus on platform-based revenue streams rather than a single blockbuster drug. This can be attractive to those seeking diversified exposure to early-stage research, as Evotec’s pipeline spans numerous programs and partners. However, it also means that the company’s performance may be influenced by broader trends in R&D outsourcing, biotech funding cycles, and regulatory developments affecting clinical trials in regions where its partners operate. For investors in US healthcare and biotech sectors, Evotec can be seen as a complementary play on innovation and collaboration rather than a direct competitor to US development-stage biotechs focused on individual assets.

Conclusion

Evotec SE continues to position itself as a global partner for drug discovery and early development, combining service revenues with the potential upside of milestones and royalties from partnered pipelines. Its Q1 2025 update and subsequent communications underline an ongoing focus on platform investments, scientific capabilities, and collaboration with large pharma and biotech players, while the decision to delist from Nasdaq shifts trading activity primarily to the Frankfurt market. For US-focused investors, Evotec offers indirect exposure to a broad array of early-stage programs linked to major healthcare companies, but this comes with the usual scientific and regulatory risks of drug development, as well as the additional considerations of currency and foreign-market trading dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.